CUREVAC NV (CVAC) Stock Fundamental Analysis
NASDAQ:CVAC - NL0015436031 - Common Stock
5.39 USD
+0.01 (+0.19%)
We assign a fundamental rating of 6 out of 10 to CVAC. CVAC was compared to 547 industry peers in the Biotechnology industry. CVAC has an excellent financial health rating, but there are some minor concerns on its profitability. CVAC has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year CVAC was profitable.
CVAC had a positive operating cash flow in the past year.
CVAC had negative earnings in 4 of the past 5 years.
In multiple years CVAC reported negative operating cash flow during the last 5 years.
1.2 Ratios
The Return On Assets of CVAC (24.34%) is better than 97.62% of its industry peers.
CVAC has a better Return On Equity (27.94%) than 97.26% of its industry peers.
CVAC's Return On Invested Capital of 24.75% is amongst the best of the industry. CVAC outperforms 97.99% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.34% | ||
| ROE | 27.94% | ||
| ROIC | 24.75% |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of CVAC (34.50%) is better than 96.89% of its industry peers.
CVAC has a Operating Margin of 37.87%. This is amongst the best in the industry. CVAC outperforms 98.17% of its industry peers.
The Gross Margin of CVAC (87.59%) is better than 89.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 37.87% | ||
| PM (TTM) | 34.5% | ||
| GM | 87.59% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CVAC has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, CVAC has about the same amount of shares outstanding.
The number of shares outstanding for CVAC has been increased compared to 5 years ago.
CVAC has a better debt/assets ratio than last year.
2.2 Solvency
CVAC has an Altman-Z score of 9.98. This indicates that CVAC is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 9.98, CVAC belongs to the best of the industry, outperforming 85.92% of the companies in the same industry.
CVAC has a debt to FCF ratio of 0.26. This is a very positive value and a sign of high solvency as it would only need 0.26 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 0.26, CVAC belongs to the best of the industry, outperforming 96.16% of the companies in the same industry.
CVAC has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
CVAC's Debt to Equity ratio of 0.05 is on the low side compared to the rest of the industry. CVAC is outperformed by 60.51% of its industry peers.
Although CVAC does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.26 | ||
| Altman-Z | 9.98 |
ROIC/WACC3.44
WACC7.19%
2.3 Liquidity
CVAC has a Current Ratio of 7.65. This indicates that CVAC is financially healthy and has no problem in meeting its short term obligations.
CVAC's Current ratio of 7.65 is fine compared to the rest of the industry. CVAC outperforms 71.85% of its industry peers.
A Quick Ratio of 7.64 indicates that CVAC has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 7.64, CVAC is in the better half of the industry, outperforming 71.85% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.65 | ||
| Quick Ratio | 7.64 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 166.39% over the past year.
The Revenue has grown by 787.58% in the past year. This is a very strong growth!
CVAC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 98.42% yearly.
EPS 1Y (TTM)166.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.81%
Revenue 1Y (TTM)787.58%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-92.78%
3.2 Future
CVAC is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -22.50% yearly.
CVAC is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -11.17% yearly.
EPS Next Y-165.87%
EPS Next 2Y-62.26%
EPS Next 3Y-31.61%
EPS Next 5Y-22.5%
Revenue Next Year-84.64%
Revenue Next 2Y-56.35%
Revenue Next 3Y-32.7%
Revenue Next 5Y-11.17%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
CVAC is valuated cheaply with a Price/Earnings ratio of 5.73.
Based on the Price/Earnings ratio, CVAC is valued cheaper than 97.99% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.14, CVAC is valued rather cheaply.
The Forward Price/Earnings Ratio is negative for CVAC. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.73 | ||
| Fwd PE | N/A |
4.2 Price Multiples
98.72% of the companies in the same industry are more expensive than CVAC, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, CVAC is valued cheaply inside the industry as 98.90% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.31 | ||
| EV/EBITDA | 2.94 |
4.3 Compensation for Growth
CVAC has a very decent profitability rating, which may justify a higher PE ratio.
CVAC's earnings are expected to decrease with -31.61% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-62.26%
EPS Next 3Y-31.61%
5. Dividend
5.1 Amount
CVAC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:CVAC (8/28/2025, 11:50:39 AM)
5.39
+0.01 (+0.19%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners4.6%
Inst Owner Change40.49%
Ins Owners0.12%
Ins Owner ChangeN/A
Market Cap1.21B
Analysts72.31
Price Target4.92 (-8.72%)
Short Float %0.77%
Short Ratio0.54
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.37%
Min EPS beat(2)-18.68%
Max EPS beat(2)35.41%
EPS beat(4)2
Avg EPS beat(4)39.95%
Min EPS beat(4)-18.68%
Max EPS beat(4)161.44%
EPS beat(8)3
Avg EPS beat(8)0.33%
EPS beat(12)5
Avg EPS beat(12)-6.4%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)15.68%
Min Revenue beat(2)-86.88%
Max Revenue beat(2)118.24%
Revenue beat(4)3
Avg Revenue beat(4)139.54%
Min Revenue beat(4)-86.88%
Max Revenue beat(4)366.65%
Revenue beat(8)4
Avg Revenue beat(8)58.85%
Revenue beat(12)5
Avg Revenue beat(12)30.03%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.9%
PT rev (3m)-22.26%
EPS NQ rev (1m)0%
EPS NQ rev (3m)23.96%
EPS NY rev (1m)0%
EPS NY rev (3m)8.76%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.53%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.73 | ||
| Fwd PE | N/A | ||
| P/S | 2 | ||
| P/FCF | 7.31 | ||
| P/OCF | 6.67 | ||
| P/B | 1.62 | ||
| P/tB | 1.68 | ||
| EV/EBITDA | 2.94 |
EPS(TTM)0.94
EY17.44%
EPS(NY)-0.54
Fwd EYN/A
FCF(TTM)0.74
FCFY13.68%
OCF(TTM)0.81
OCFY15%
SpS2.7
BVpS3.33
TBVpS3.2
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.34% | ||
| ROE | 27.94% | ||
| ROCE | 29.12% | ||
| ROIC | 24.75% | ||
| ROICexc | 70.54% | ||
| ROICexgc | 78.69% | ||
| OM | 37.87% | ||
| PM (TTM) | 34.5% | ||
| GM | 87.59% | ||
| FCFM | 27.34% |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.71
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.26 | ||
| Debt/EBITDA | 0.15 | ||
| Cap/Depr | 74.88% | ||
| Cap/Sales | 2.65% | ||
| Interest Coverage | 85.86 | ||
| Cash Conversion | 72.42% | ||
| Profit Quality | 79.25% | ||
| Current Ratio | 7.65 | ||
| Quick Ratio | 7.64 | ||
| Altman-Z | 9.98 |
F-Score8
WACC7.19%
ROIC/WACC3.44
Cap/Depr(3y)242.45%
Cap/Depr(5y)397%
Cap/Sales(3y)81.47%
Cap/Sales(5y)93.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)166.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.81%
EPS Next Y-165.87%
EPS Next 2Y-62.26%
EPS Next 3Y-31.61%
EPS Next 5Y-22.5%
Revenue 1Y (TTM)787.58%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-92.78%
Revenue Next Year-84.64%
Revenue Next 2Y-56.35%
Revenue Next 3Y-32.7%
Revenue Next 5Y-11.17%
EBIT growth 1Y168.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-152.22%
EBIT Next 3Y-32.99%
EBIT Next 5Y10.78%
FCF growth 1Y142.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y162.99%
OCF growth 3YN/A
OCF growth 5YN/A